Clinical Pharmacology & Therapeutics · 2010 · 107 citations · 20 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPharmacogeneticsPharmacogenomicsClinical Implementation Of PharmacogeneticsDrug Metabolism GeneticsMetabolism VariabilityNicotine DependenceNicotine PharmacologyPharmacogenetic TestingClinical Pharmacology EvidenceClinical Pharmacology ReviewNicotine MetabolismNicotine PharmacokineticsPlacebo-controlled Efficacy AssessmentReduced Rates
In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.
20
Biochemical verification of tobacco use and cessation
Neal L. Benowitz, Peyton Jacob, Karen Ahijevych et al. · Nicotine & Tobacco Research · 2002 · 1.8K citations · Full text